• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Tamoxifen ("Nolvadex"): a review.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Clemons, Mark
    Danson, Sarah
    Howell, Anthony
    Affiliation
    Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. mark.clemons@tsrcc.on.ca
    Issue Date
    2002-08
    
    Metadata
    Show full item record
    Abstract
    Tamoxifen has been used in the management of breast cancer for over 30 years. Since its introduction for the treatment of advanced breast cancer, its indications have increased to include the treatment of early breast cancer, ductal carcinoma in situ, and more recently for breast cancer chemoprevention. Tamoxifen has a good tolerability profile and moreover, unlike many other endocrine therapies, it is efficacious in both pre- and postmenopausal women.It is the combination of efficacy and tolerability that allows tamoxifen to maintain its position as the hormonal treatment of choice for most patients with oestrogen-receptor positive breast cancer. Ongoing studies will provide further information about the optimal duration of tamoxifen therapy and how it compares with the newer aromatase inhibitors.
    Citation
    Tamoxifen ("Nolvadex"): a review. 2002, 28 (4):165-80 Cancer Treat. Rev.
    Journal
    Cancer Treatment Reviews
    URI
    http://hdl.handle.net/10541/81235
    PubMed ID
    12363457
    Type
    Article
    Language
    en
    ISSN
    0305-7372
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
    • Authors: Goss PE, Strasser K
    • Issue date: 2002
    • Aromatase inhibitors for breast cancer: pharmacoeconomic considerations.
    • Authors: Higa GM
    • Issue date: 2001 Jun
    • [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    • Authors: de Cremoux P, Diéras V, Poupon MF, Magdelénat H, Sigal-Zafrani B, Fourquet A, Pierga JY
    • Issue date: 2004 Dec
    • Biological rationale for endocrine therapy in breast cancer.
    • Authors: Miller WR
    • Issue date: 2004 Mar
    • Shifting paradigms in hormonal therapy for breast cancer.
    • Authors: Grana G
    • Issue date: 2004 Sep
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.